[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201407866XA - Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector - Google Patents

Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector

Info

Publication number
SG11201407866XA
SG11201407866XA SG11201407866XA SG11201407866XA SG11201407866XA SG 11201407866X A SG11201407866X A SG 11201407866XA SG 11201407866X A SG11201407866X A SG 11201407866XA SG 11201407866X A SG11201407866X A SG 11201407866XA SG 11201407866X A SG11201407866X A SG 11201407866XA
Authority
SG
Singapore
Prior art keywords
international
cell
virus vector
rna virus
strand rna
Prior art date
Application number
SG11201407866XA
Inventor
Marian Wiegand
Original Assignee
Amvac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amvac Ag filed Critical Amvac Ag
Publication of SG11201407866XA publication Critical patent/SG11201407866XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18851—Methods of production or purification of viral material
    • C12N2760/18852—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18861—Methods of inactivation or attenuation
    • C12N2760/18862—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/178344 A1 (51) International Patent Classification: C12N15/86 (2006.01) C12N 5/071 (2010.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/001547 24 May 2013 (24.05.2013) English English (30) Priority Data: 12004148.8 61/652,913 30 May 2012 (30.05.2012) EP 30 May 2012 (30.05.2012) US (71) Applicant: AMVAC AG [CH/CH]; Metallstr. 4, CH-6300 Zug (CH). (72) Inventor: WIEGAND, Marian; Milchstrasse 1, 81667 Muenchen (DE). (74) Agent: RICKER, Mathias; Wallinger Ricker Schlotter Tostmann, Zweibriickenstr. 5-7, 80331 Muenchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: METHOD FOR EXPRESSION OF HETEROLOGOUS PROTEINS USING A RECOMBINANT NEGAT- IVE-STRAND RNA VIRUS VECTOR •t •t m oo i> i-H cn i-H o CJ o & u (0 PS 03 •Q 0.8 0.6H 0.4 0.2 u .> ro g 0.015- g- 0.010- ifl 0.005- v D. 0.000- x 07 r* i & £ Nanog BBS Pi •m fsssa ^ day after transduction Fig. 3 m 1 m (57) Abstract: The present invention provides a method of expressing at least one heterologous nucleic acid sequence in a cell, the method comprising introducing at least one het­ erologous nucleic acid sequence into cell a by infecting said cell with a recombinant negative-strand RNA virus vector comprising said at least one heterologous nucleic acid se­ quence, wherein the recombinant negative- strand RNA virus vector includes a viral genome coding for a mutated P pro - tein, which leads to a loss of the viral genome replication ability without a loss of the viral transcription ability, and wherein said at least one heterologous nucleic acid sequence encodes cellular reprogramming a or programming factor or a therapeutic protein. In addition, the present invention provides a cell or a population of cells prepared in vitro by said method as well as a pharmaceutical composition com­ prising said cell or population of cells.
SG11201407866XA 2012-05-30 2013-05-24 Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector SG11201407866XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261652913P 2012-05-30 2012-05-30
EP12004148.8A EP2669381A1 (en) 2012-05-30 2012-05-30 Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein
PCT/EP2013/001547 WO2013178344A1 (en) 2012-05-30 2013-05-24 Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector

Publications (1)

Publication Number Publication Date
SG11201407866XA true SG11201407866XA (en) 2014-12-30

Family

ID=46229168

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201701054XA SG10201701054XA (en) 2012-05-30 2013-05-24 Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201407866XA SG11201407866XA (en) 2012-05-30 2013-05-24 Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201701054XA SG10201701054XA (en) 2012-05-30 2013-05-24 Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector

Country Status (15)

Country Link
US (1) US20150133531A1 (en)
EP (2) EP2669381A1 (en)
JP (2) JP2015523065A (en)
KR (2) KR20150014482A (en)
CN (2) CN108192921A (en)
AU (1) AU2013270018B2 (en)
CA (1) CA2873814A1 (en)
EA (1) EA201492202A1 (en)
IL (1) IL235381A0 (en)
IN (1) IN2014DN08960A (en)
MX (1) MX2014014507A (en)
RU (1) RU2014152275A (en)
SG (2) SG10201701054XA (en)
WO (1) WO2013178344A1 (en)
ZA (1) ZA201407468B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2251034T (en) 2005-12-02 2018-05-22 Icahn School Med Mount Sinai Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
US10022431B2 (en) 2010-02-10 2018-07-17 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US9517258B2 (en) 2012-03-15 2016-12-13 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
CA2905272A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
SG10201801562PA (en) 2014-02-27 2018-04-27 Viralytics Ltd Combination method for treatment of cancer
WO2015143221A1 (en) 2014-03-19 2015-09-24 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2015143223A1 (en) 2014-03-19 2015-09-24 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CA2944492A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US11672830B2 (en) * 2016-04-15 2023-06-13 Temple University-Of The Commonwealth System Of Higher Education MicroRNA-294 and Lin28A as a driver of cardiac tissue proliferation in response to pathological injury
EP4056189A1 (en) * 2016-09-30 2022-09-14 Mayo Foundation for Medical Education and Research Viral vectors for nuclear reprogramming
JP6949468B2 (en) * 2016-10-17 2021-10-13 ルプレヒト−カールス−ウニベルジテート ハイデルベルク Measles virus encoding tumor antigen
US10633689B2 (en) * 2016-11-07 2020-04-28 Spark Therapeutics, Inc. Rab Escort Protein potency assay
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
AU2019261646A1 (en) * 2018-04-27 2020-11-12 Spacecraft Seven, Llc Gene therapy for CNS degeneration
CN108715868A (en) * 2018-05-31 2018-10-30 深圳市免疫基因治疗研究院 A kind of Gaucher slow virus carriers, slow virus and its preparation method and application
CN109666727B (en) * 2018-12-29 2020-11-06 中国药科大学 Application of micro RNA for high-activity inhibition of PCSK9 expression
CN110178792B (en) * 2019-05-07 2021-11-16 哈尔滨医科大学 Method for constructing atherosclerosis vulnerable plaque mouse model
CN112795578B (en) * 2021-02-07 2022-06-10 沈阳农业大学 Magnaporthe grisea MoPTEN gene and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005006388A1 (en) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replication-deficient RNA viruses as vaccines
KR20110046472A (en) 2008-07-16 2011-05-04 디나벡크 가부시키가이샤 How to prepare reprogrammed cells using chromosomal non-inserted viral vectors
JP5633075B2 (en) * 2009-05-18 2014-12-03 独立行政法人産業技術総合研究所 Vector material for preparing pluripotent stem cells and method for preparing pluripotent stem cells using the same

Also Published As

Publication number Publication date
CA2873814A1 (en) 2013-12-05
JP2015523065A (en) 2015-08-13
US20150133531A1 (en) 2015-05-14
AU2013270018B2 (en) 2019-02-14
EA201492202A1 (en) 2015-03-31
CN104379752A (en) 2015-02-25
KR20150014482A (en) 2015-02-06
IL235381A0 (en) 2014-12-31
JP2018023388A (en) 2018-02-15
WO2013178344A1 (en) 2013-12-05
EP2855683A1 (en) 2015-04-08
AU2013270018A1 (en) 2014-12-18
MX2014014507A (en) 2015-05-12
EP2669381A1 (en) 2013-12-04
CN108192921A (en) 2018-06-22
SG10201701054XA (en) 2017-04-27
IN2014DN08960A (en) 2015-05-22
KR20200037835A (en) 2020-04-09
RU2014152275A (en) 2016-07-20
ZA201407468B (en) 2022-11-30

Similar Documents

Publication Publication Date Title
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201807378SA (en) Trans-replicating rna
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201909777YA (en) Modulatory polynucleotides
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201907846VA (en) Therapeutic rna
SG11201908280SA (en) "chimeric molecules and uses thereof"
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201807912SA (en) Vaccine against rsv
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201809643UA (en) Compositions and methods of treating huntington's disease
SG11201811184UA (en) Lag -3 binding members
SG11201807188VA (en) Modified cells for immunotherapy
SG11201909203WA (en) Tissue selective transgene expression
SG11201807374WA (en) Rna replicon for versatile and efficient gene expression
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201811048UA (en) Single-cell transcript sequencing
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201803642WA (en) Bacteria-based protein delivery
SG11201407595UA (en) Generation of human ips cells by a synthetic self- replicative rna
SG11201900400QA (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
SG11201807134RA (en) Transposon system and methods of use